PDL BioPharma Inc (PDLI)

2.34
NASDAQ : Health Care
Prev Close 2.34
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.93 / 3.77
Avg Volume 1.89M
Exchange NASDAQ
Shares Outstanding 160.98M
Market Cap 373.48M
EPS 0.40
P/E Ratio 25.78
Div & Yield 0.20 (8.60%)

Latest News

Sarepta Pops on Bullish Sentiment Around Duchenne Therapy, PDL Up on Merck Deal: Biotech Movers

Sarepta Pops on Bullish Sentiment Around Duchenne Therapy, PDL Up on Merck Deal: Biotech Movers

Sarepta Therapeutics, Paratek Pharmaceuticals and PDL BioPharma were among the biotech stock movers in premarket trading on Monday.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CPLP, IRDM Downgrades: GPT, MBI, PDLI, PWOD, TLRD Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Argos Plummets 72%, Leads Biotech Movers

Argos Plummets 72%, Leads Biotech Movers

Also falling was Global Blood Therapeutics.

Short Interest Increases 29.7% For PDLI

The most recent short interest data has been released for the 01/31/2017 settlement date, which shows a 2,792,771 share increase in total short interest for PDL BioPharma Inc , to 12,191,416, an increase of 29.71% since 01/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

LENSAR® Launches Streamline™ III To Assist Cataract Surgeons In Managing And Improving Astigmatism Treatment For Optimal Visual Outcomes

LENSAR® Launches Streamline™ III To Assist Cataract Surgeons In Managing And Improving Astigmatism Treatment For Optimal Visual Outcomes

LENSAR, Inc., a global leader in next generation femtosecond laser technology for refractive cataract surgery, today announced Streamline III, its third system upgrade in less than two years.

PDL BioPharma Stock Sees Short Interest Decline 14.5%

PDL BioPharma Stock Sees Short Interest Decline 14.5%

The most recent short interest data has been released for the 11/15/2016 settlement date, which shows a 999,222 share decrease in total short interest for PDL BioPharma Inc , to 5,892,922, a decrease of 14.50% since 10/31/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Eli Lilly's Alzheimer's Drug Study Results Are Coming -- Here's What Investors Need to Know

Eli Lilly's Alzheimer's Drug Study Results Are Coming -- Here's What Investors Need to Know

In a few weeks, investors will know if Lilly's solanezumab is a groundbreaking treatment for Alzheimer's or another drug casualty to a disease that has eluded pharmaceutical companies for years.

Short Interest In PDL BioPharma Declines 14.2%

Short Interest In PDL BioPharma Declines 14.2%

The most recent short interest data has been released for the 09/15/2016 settlement date, which shows a 1,140,664 share decrease in total short interest for PDL BioPharma Inc , to 6,915,394, a decrease of 14.16% since 08/31/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Short Interest Moves 28% Lower For PDLI

Short Interest Moves 28% Lower For PDLI

The most recent short interest data has been released for the 08/15/2016 settlement date, which shows a 3,055,374 share decrease in total short interest for PDL BioPharma Inc , to 7,833,748, a decrease of 28.06% since 07/29/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

PDL BioPharma (PDLI) Stock Plummets on Q2 Revenue Miss

PDL BioPharma (PDLI) Stock Plummets on Q2 Revenue Miss

Following Thursday's closing bell, PDL BioPharma (PDLI) reported lower-than-expected revenue for the 2016 second quarter.

Dividend Action Aplenty This Week

Earnings season is often a busy period for dividend hikes and cuts, and this one has been no exception.

Today's Weak On High Volume Stock: PDL BioPharma (PDLI)

Today's Weak On High Volume Stock: PDL BioPharma (PDLI)

Trade-Ideas LLC identified PDL BioPharma (PDLI) as a weak on high relative volume candidate